AngioDynamics Inc (NASDAQ:ANGO) Surpasses Q1 Earnings Estimates and Raises Fiscal 2026 Outlook

AngioDynamics Inc (NASDAQ:ANGO) reported financial results for the first quarter of fiscal year 2026, delivering a performance that notably exceeded analyst expectations on both the top and bottom lines. The medical technology company's results, coupled with an improved financial outlook for the full year, appear to have generated a positive market response.

Earnings and Revenue Performance Versus Estimates

The company's first-quarter results demonstrated significant strength, particularly in its higher-growth Med Tech segment. AngioDynamics surpassed revenue estimates and delivered a smaller-than-expected loss.

• Revenue: Reported net sales of $75.7 million, exceeding analyst estimates of approximately $74.2 million.
• Earnings Per Share (EPS): Posted an adjusted loss per share of $0.10, which was better than the anticipated loss of $0.12 per share.

This outperformance was primarily fueled by the company's strategic Med Tech platforms. The Med Tech segment, which includes the Auryon atherectomy, thrombus management, and NanoKnife systems, saw sales surge 26.1% year-over-year to $35.3 million.

Market Reaction and Price Action

The market's initial reaction to the earnings beat and raised guidance has been positive. In pre-market trading following the announcement, the stock showed significant upward momentum. This positive price action suggests that investors are rewarding the company for its strong operational execution and the continued rapid growth of its key technology platforms, which have now delivered over 20% growth for four consecutive quarters.

Updated Financial Guidance

Management raised its financial outlook for fiscal year 2026, indicating growing confidence in the business trajectory. The new guidance brackets current analyst estimates for the full year, setting a positive tone.

• Net Sales Guidance: Increased to a range of $308 - $313 million, up from the previous range of $305 - $310 million. The midpoint of this new range sits just above the analyst consensus of $313.3 million.
• Med Tech Growth: The projected growth rate for the Med Tech segment was raised to 14% - 16%, from the prior 12% - 15%.
• Adjusted EBITDA: The forecast was significantly increased to a range of $6.0 - $10.0 million, up from $3.0 - $8.0 million previously.
• Adjusted EPS: Guidance for the full-year adjusted loss per share was improved to a range of ($0.33) – ($0.23), from ($0.35) – ($0.25) previously. The midpoint of this new range is more optimistic than the analyst consensus estimate of a $0.32 loss.

Key Operational Highlights

Beyond the financial figures, the quarter was marked by several significant clinical and operational milestones that underscore the company's focus on evidence-based growth:

• Strong Med Tech Growth: All three Med Tech platforms—Auryon, Mechanical Thrombectomy (AngioVac/AlphaVac), and NanoKnife—delivered robust double-digit sales growth.
• Clinical Trial Progress: The company enrolled the first patients in two key clinical trials: the AMBITION BTK trial for the Auryon System and the RECOVER-AV trial for the AlphaVac System, aimed at expanding clinical evidence and treatment applications.
• Positive Clinical Publication: Results from the NanoKnife PRESERVE study for prostate cancer treatment were published in the prominent journal European Urology, reinforcing the technology's value proposition in preserving patient quality of life.
• Solid Financial Position: The company ended the quarter with $38.8 million in cash and maintains a debt-free balance sheet, reiterating its expectation to be free cash flow positive for the full fiscal year.

Conclusion

AngioDynamics' first-quarter results paint a picture of a company successfully executing its strategic shift towards high-growth Med Tech platforms. The decisive beats on revenue and earnings, combined with a substantially improved full-year outlook, provide a strong fundamental basis for the positive investor sentiment observed in early market reactions. The continued momentum in its core businesses and advancements in its clinical pipeline suggest the company is well-positioned for sustained growth.

For a more detailed look at AngioDynamics' earnings history and future estimates, you can review the data here.

Disclaimer: This article is for informational purposes only and is not intended as investment advice. The author does not have a position in this stock. All investment decisions involve risk, and readers should conduct their own research before making any investment decisions.